Draft:Boster Biological Technology
| Boster Bio | |
| Type | Private |
| Industry | Biotechnology |
| Founded | 1993 |
| Founder | Steven Xia |
| Headquarters | , United States |
| Products | Antibodies, ELISA kits, recombinant proteins, research reagents |
| Website | www |
Boster Biological Technology, doing business as Boster Bio, is a privately held biotechnology company that develops and manufactures antibodies, ELISA kits, recombinant proteins, and related reagents and services for life science research. Its products are used in laboratory techniques including immunohistochemistry, Western blotting, and flow cytometry, in fields such as immunology, oncology, and neuroscience.[1][2]
History
[edit]Boster Biological Technology was founded in 1993 in China by histologist Steven Xia as a small family-owned business supplying histology reagents. The company later expanded its antibody catalog and, in 2012, established a United States headquarters in Pleasanton, California.
Research use
[edit]Boster Bio reagents are cited in peer-reviewed literature, typically in the materials and methods sections, as the source of specific antibodies or ELISA kits.[3]
In cancer research, the company's products have been used in studies of thalidomide and vasculogenic mimicry in melanoma,[1] glutamine deprivation and CD8+ T cell function in hepatocellular carcinoma,[4] ozonated water in a mouse Ehrlich tumor model,[5] HLA export by melanoma cells and immune evasion,[6] and response and resistance to inotuzumab ozogamicin in B-cell acute lymphoblastic leukemia.[7]
In neuroscience and pain research, they have been used in studies of transplanted microencapsulated neural stem cells and olfactory ensheathing cells in models of neuropathic pain involving P2X receptors.[2][8][9]
Other studies citing the company's reagents include research on vascular smooth muscle cell calcification,[10] the NLRP3 inflammasome in chronic rhinosinusitis with nasal polyps,[11] serum macrophage migration inhibitory factor in major depressive disorder,[3] kaempferol in hyperuricemia with gouty arthritis,[12] and OAS proteins in psoriasis.[13]
See also
[edit]References
[edit]- 1 2 "Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma". Journal of Experimental & Clinical Cancer Research. 27 (1): 60. 2008. doi:10.1186/1756-9966-27-60.
- 1 2 "Microencapsulated neural stem cells inhibit sciatic nerve injury-induced pain by reducing P2X4 receptor expression". Frontiers in Cell and Developmental Biology. 2021. doi:10.3389/fcell.2021.656780.
- 1 2 "Elevated Serum Macrophage Migration Inhibitory Factor Levels are Associated With Major Depressive Disorder". Clinical Pathology. 2023. doi:10.1177/2632010X231220841.
- ↑ "Glutamine deprivation impairs function of infiltrating CD8+ T cells in hepatocellular carcinoma by inducing mitochondrial damage and apoptosis". World Journal of Gastroenterology. 2022.
- ↑ "Ozonated Water Modulates Cell Proliferation and Vascular Density in Solid Ehrlich Tumor of Mice". Cancers. 2026. doi:10.3390/cancers18050733.
- ↑ "HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion". Cell. 2025. doi:10.1016/j.cell.2025.11.020.
- ↑ "Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL". Blood. 2024. doi:10.1182/blood.2024023930.
- ↑ "Transplantation of microencapsulated neural stem cells inhibits neuropathic pain mediated by P2X7 receptor overexpression". Biochemical and Biophysical Research Communications. 2020.
- ↑ "Transplantation of microencapsulated olfactory ensheathing cells inhibits the P2X2 receptor over-expression mediated neuropathic pain in the L4–5 spinal cord". International Journal of Neuroscience. 2020.
- ↑ "miR32-5p promoted vascular smooth muscle cell calcification by upregulating TNFα in the microenvironment". BMC Immunology. 2019. doi:10.1186/s12865-019-0324-x.
- ↑ "Role of NLRP3 inflammasome in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps". Inflammation. 2017. doi:10.1007/s10753-016-0442-z.
- ↑ "Kaempferol attenuates hyperuricemia combined with gouty arthritis via urate transporters and NLRP3/NF-κB pathway modulation". iScience. 2024. doi:10.1016/j.isci.2024.111186.
- ↑ "OAS1, OAS2, and OAS3 Contribute to Epidermal Keratinocyte Proliferation by Regulating Cell Cycle and Augmenting IFN-1‒Induced Jak1‒Signal Transducer and Activator of Transcription 1 Phosphorylation in Psoriasis". Journal of Investigative Dermatology. 2022. doi:10.1016/j.jid.2022.02.018.